2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000

Alar Pharmaceuticals Inc., a new drug development company focused on long-acting release drug products, has announced that it concluded its pre-Investigational New Drug (pre-IND) meeting with U.S. Food and Drug Administration (FDA) for ALA-3000 on August 21, 2020. ALA-3000 is a developing long-acting new drug to treat patients with treatment-resistant depression (TRD), which is designed with specific features to have safety benefits. In the written response, US FDA agrees with…

Comments Off on 2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000